Your browser doesn't support javascript.
loading
A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.
Mulder, Skander; Hammarstedt, Ann; Nagaraj, Sunil B; Nair, Viji; Ju, Wenjun; Hedberg, Jonatan; Greasley, Peter J; Eriksson, Jan W; Oscarsson, Jan; Heerspink, Hiddo J L.
Afiliação
  • Mulder S; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Hammarstedt A; AstraZeneca, BioPharmaceuticals R&D, Mölndal, Sweden.
  • Nagaraj SB; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Nair V; Michigan University, Ann Arbor, Michigan, USA.
  • Ju W; Michigan University, Ann Arbor, Michigan, USA.
  • Hedberg J; AstraZeneca, BioPharmaceuticals R&D, Mölndal, Sweden.
  • Greasley PJ; AstraZeneca, BioPharmaceuticals R&D, Mölndal, Sweden.
  • Eriksson JW; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Oscarsson J; AstraZeneca, BioPharmaceuticals R&D, Mölndal, Sweden.
  • Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Diabetes Obes Metab ; 22(7): 1157-1166, 2020 07.
Article em En | MEDLINE | ID: mdl-32115853

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Simportadores / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Simportadores / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article